Multi-specific Fab fusion proteins comprising a CD3-binding Fab fragment with N-terminal fusion to binding domains and methods of use

Inventor: Hongxing Zhou (Bellevue, WA)

Assignee: Evive Biotech Ltd.

A61K39/39558 C07K14/705 C07K16/2809 C07K16/30 C07K2317/31 C07K2317/55 C07K2319/00 C07K2319/74

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,013,800
App. No.: 14/479,203
Granted: May 25, 2021
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

Claims (30)

1. A multi-specific Fab fusion protein comprising: (a) a Fab fragment that binds to the N-terminus of CD3 epsilon corresponding to the N-terminal amino acids 1-27 of SEQ ID NO: 18, wherein the Fab fragment comprises a first chain comprising an immunoglobulin light chain variable (VL) domain and a second chain comprising an immunoglobulin heavy chain variable (VH) domain; (b) a fusion moiety A linked to the VL domain of the Fab fragment via a first linker disposed between the C-terminus of the fusion moiety A and the N-terminus of the VL domain; and (c) a fusion moiety B linked to the VH domain of the Fab fragment via a second linker disposed between the C-terminus of the fusion moiety B and the N-terminus of the VH domain, wherein the fusion moiety A comprises a cell surface antigen binding domain comprising an antigen binding fragment comprising a VH domain and a VL domain, wherein the fusion moiety B comprises a cell surface antigen binding domain comprising an antigen binding fragment comprising a VH domain and a VL domain; wherein the VL domain of the Fab fragment comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 28; and the VH domain of the Fab fragment comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 23, a CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

wherein:

(1) the VH domain of the Fab fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 38, 42, 46, 50, and 54; or

(2) the VL domain of the Fab fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 56, 58, 62, 66, and 70.

2. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B bind to the same cell surface antigen.

3. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B bind to different cell surface antigens.

4. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B bind to a cell surface antigen selected from a group consisting of: FcγRIIb, CD28, CTLA-4, FAS, FGFR1, FGFR2, FGFR3, FGFR4, GITR, LTβR, TLR, TRAIL receptor 1, CEA, PSMA, BCMA, CAIX, cMet, EGFR1, Her2/neu, ErbB3, EpCAM, Folate receptor, Ephrin receptor, TRAIL receptor 2, CD19, CD20, CD30, CD33, CD40, CD37, CD38, and CD138.

5. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B are generated from phage display, yeast display, or a human antibody gene transgenic mouse.

6. The multi-specific Fab fusion protein of claim 1 , wherein the constant region of the light chain (CL region) comprises a knob or hole mutation and the heavy chain constant region 1 (CH1 region) comprises a corresponding knob or hole mutation such that the CL region and the CH1 region stably interact.

7. Isolated polynucleotide or polynucleotides encoding the multi-specific Fab fusion protein of claim 1 .

8. An isolated expression vector comprising the isolated polynucleotide or polynucleotides of claim 7 .

9. An isolated host cell comprising the vector of claim 8 .

10. A method of expressing a multi-specific Fab fusion protein by culturing the host cell of claim 9 under conditions in which the vector expresses the encoded multi-specific Fab fusion protein.

11. A pharmaceutical composition comprising the multi-specific Fab fusion protein of claim 1 and a pharmaceutically acceptable carrier.

12. A method for treating a cancer comprising administering an effective amount of the pharmaceutical composition of claim 11 to a subject having the cancer, wherein the cancer expresses a cell surface antigen to which the multi-specific Fab fusion protein can bind.

13. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B bind to EpCAM.

14. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B bind to CD19.

15. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A binds to EpCAM and the fusion moiety B binds to CD19, or the fusion moiety A binds to CD19 and the fusion moiety B binds to EpCAM.

16. The multi-specific Fab fusion protein of claim 1 , wherein the VH domain of the Fab fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 38, 42, 46, 50, and 54.

17. The multi-specific Fab fusion protein of claim 1 , wherein the VL domain of the Fab fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 56, 58, 62, 66, and 70.

18. The multi-specific Fab fusion protein of claim 13 , wherein each antigen binding fragment of the fusion moiety A and the fusion moiety B: 1) comprises a VH domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 141; and a VL domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 142, a CDR2 comprising the amino acid sequence of SEQ ID NO: 143, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 144; 2) comprises a VH domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 145, a CDR2 comprising the amino acid sequence of SEQ ID NO: 146, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 147; and a VL domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 148, a CDR2 comprising the amino acid sequence of SEQ ID NO: 149, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 150; 3) comprises a VH domain comprising amino acid residues 1-118 of SEQ ID NO: 78 and a VL domain comprising amino acid residues 134-246 of SEQ ID NO: 78; 4) comprises a VH domain comprising amino acid residues 1-118 of SEQ ID NO: 88 and a VL domain comprising amino acid residues 134-246 of SEQ ID NO: 88; 5) comprises a VH domain comprising amino acid residues 1-116 of SEQ ID NO: 94 and a VL domain comprising amino acid residues 132-241 of SEQ ID NO: 94; or 6) comprises an scFv comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78, 88, and 94.

19. The multi-specific Fab fusion protein of claim 1 , wherein each of the antigen binding fragment of the fusion moiety A and the fusion moiety B is an scFv.

20. A multi-specific Fab fusion protein comprising: (a) a Fab fragment that binds to the N-terminus of CD3 epsilon corresponding to the N-terminal amino acids 1-27 of SEQ ID NO: 18, wherein the Fab fragment comprises a first chain comprising an immunoglobulin VL domain and a second chain comprising an immunoglobulin VH domain; (b) a fusion moiety A linked to the VL domain of the Fab fragment via a first linker disposed between the C-terminus of the fusion moiety A and the N-terminus of the VL domain; and (c) a fusion moiety B linked to the VH domain of the Fab fragment via a second linker disposed between the C-terminus of the fusion moiety B and the N-terminus of the VH domain, wherein the fusion moiety A comprises an EpCAM-binding fragment, wherein the fusion moiety B comprises an EpCAM-binding fragment, wherein each EpCAM-binding fragment of the fusion moiety A and the fusion moiety B: 1) comprises a VH domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 139, a CDR2 comprising the amino acid sequence of SEQ ID NO: 140, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 141; and a VL domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 142, a CDR2 comprising the amino acid sequence of SEQ ID NO: 143, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 144; 2) comprises a VH domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 145, a CDR2 comprising the amino acid sequence of SEQ ID NO: 146, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 147; and a VL domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 148, a CDR2 comprising the amino acid sequence of SEQ ID NO: 149, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 150; 3) comprises a VH domain comprising amino acid residues 1-118 of SEQ ID NO: 78 and a VL domain comprising amino acid residues 134-246 of SEQ ID NO: 78; 4) comprises a VH domain comprising amino acid residues 1-118 of SEQ ID NO: 88 and a VL domain comprising amino acid residues 134-246 of SEQ ID NO: 88; 5) comprises a VH domain comprising amino acid residues 1-116 of SEQ ID NO: 94 and a VL domain comprising amino acid residues 132-241 of SEQ ID NO: 94; or 6) comprises an scFv comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78, 88, and 94.

21. The multi-specific Fab fusion protein of claim 20 , wherein each EpCAM-binding fragment of the fusion moiety A and the fusion moiety B is an scFv.

22. The multi-specific Fab fusion protein of claim 20 , wherein the Fab fragment is humanized.

23. A pharmaceutical composition comprising the multi-specific Fab fusion protein of claim 20 and a pharmaceutically acceptable carrier.

24. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B are identical in amino acid sequence.

25. The multi-specific Fab fusion protein of claim 1 , wherein the fusion moiety A and the fusion moiety B comprise different amino acid sequences.

26. The multi-specific Fab fusion protein of claim 20 , wherein the fusion moiety A and the fusion moiety B are identical in amino acid sequence.

27. The multi-specific Fab fusion protein of claim 20 , wherein the fusion moiety A and the fusion moiety B comprise different amino acid sequences.

Assignments (7)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2026

From: ITABMED (HK) LIMITED

To: ITABMED CO., LTD.

Reel/Frame 074003/0001 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2021